Skip to main
ACLX

Arcellx (ACLX) Stock Forecast & Price Target

Arcellx (ACLX) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 22%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Arcellx Inc.'s robust development pipeline and significant advancements in CAR T therapy, exemplified by Carvykti's impressive average sales growth of 32% quarter-over-quarter over the last 12 quarters and a year-over-year revenue increase of 214%, highlight strong market demand. The expanding ability of community physicians to administer CAR T treatments, rising from 29% to 47% over the specified period, indicates growing accessibility and adoption of these therapies. Additionally, the anticipated performance of anito-cel and the company's innovative production techniques position Arcellx favorably within a competitive landscape, with projections suggesting the potential for substantial market share and revenues reaching approximately $4.7 billion by 2035.

Bears say

The analysis highlights concerns regarding Arcellx's product performance, particularly the high incidence of Grade 3-4 infections associated with its treatments, which raises potential safety issues that could hinder patient adoption. Additionally, lower projected sales estimates for anito-cel, in contrast to market consensus, reflect doubts about the overall CAR T market growth in myeloma, thereby negatively impacting the company's revenue outlook. Furthermore, barriers to CAR T adoption in community settings, combined with uncertainty in the development of future candidates, add to the unfavorable sentiment surrounding Arcellx's ability to capture its expected market share.

Arcellx (ACLX) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 22% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arcellx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arcellx (ACLX) Forecast

Analysts have given Arcellx (ACLX) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Arcellx (ACLX) has a Strong Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $112.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $112.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arcellx (ACLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.